Reports FY24 revenue $36.13M, consensus $37.63M. “We believe that petosemtamab’s receipt of two Breakthrough Therapy designations by the FDA – previously as monotherapy in the 2L+ treatment of r/m HNSCC and very recently, based on updated clinical efficacy, durability and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC, indicates the potential for these treatment regimens to demonstrate substantial improvement over available therapies,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus (MRUS). “We look forward to sharing the updated clinical data, including durability, for petosemtamab with pembrolizumab in 1L PD-L1+ r/m HNSCC, for the full phase 2 cohort, in the first half of 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus’s Breakthrough in HNSCC: Buy Rating Backed by FDA Support and Promising Trial Data
- Merus’s Breakthrough Therapy Designation and Strong Financials Justify Buy Rating
- Merus’ petosemtamab granted Breakthrough Therapy designation by FDA
- Target downgraded, Cisco upgraded: Wall Street’s top analyst calls
- Analyst Recommends Buy for Merus Based on Promising Petosemtamab Developments and Revenue Potential